Drug Profile
Research programme: Alzheimer's disease therapeutics - Medisyn
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Medisyn Technologies; Mount Sinai School of Medicine
- Developer Icahn School of Medicine at Mount Sinai; Medisyn Technologies
- Class
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 04 Mar 2010 Preclinical trials in Alzheimer's disease in USA (unspecified route)